Gene expression and hypoxia in breast cancer

65Citations
Citations of this article
154Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hypoxia is a feature of most solid tumors and is associated with poor prognosis in several cancer types, including breast cancer. The master regulator of the hypoxic response is the Hypoxia-inducible factor 1a (HIF--1a). It is becoming clear that HIF-1a expression alone is not a reliable marker of tumor response to hypoxia, and recent studies have focused on determining gene and microRNA (miRNA) signatures for this complex process. The results of these studies are likely to pave the way towards the development of a robust hypoxia signature for breast and other cancers that will be useful for diagnosis and therapy. In this review, we outline the existing markers of hypoxia and recently identified gene and miRNA expression signatures, and discuss their potential as prognostic and predictive biomarkers. We also highlight how the hypoxia response is being targeted in the development of cancer therapies. © 2011 BioMed Central Ltd.

Cite

CITATION STYLE

APA

Favaro, E., Lord, S., Harris, A. L., & Buffa, F. M. (2011, August 26). Gene expression and hypoxia in breast cancer. Genome Medicine. https://doi.org/10.1186/gm271

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free